Vaxcyte Net Receivables from 2010 to 2026

PCVX Stock  USD 55.57  0.58  1.03%   
Vaxcyte Net Receivables yearly trend continues to be fairly stable with very little volatility. Net Receivables is likely to outpace its year average in 2026. During the period from 2010 to 2026, Vaxcyte Net Receivables regression line of annual values had r-squared of  0.50 and arithmetic mean of  4,557,627. View All Fundamentals
 
Net Receivables  
First Reported
2020-06-30
Previous Quarter
100 K
Current Value
400 K
Quarterly Volatility
6.6 M
 
Covid
 
Interest Hikes
Check Vaxcyte financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vaxcyte's main balance sheet or income statement drivers, such as Interest Income of 132.8 M, Depreciation And Amortization of 19.1 M or Interest Expense of 0.0, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.82. Vaxcyte financial statements analysis is a perfect complement when working with Vaxcyte Valuation or Volatility modules.
  
Build AI portfolio with Vaxcyte Stock
Check out the analysis of Vaxcyte Correlation against competitors.
For more information on how to buy Vaxcyte Stock please use our How to Invest in Vaxcyte guide.
The evolution of Net Receivables for Vaxcyte provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Vaxcyte compares to historical norms and industry peers.

Latest Vaxcyte's Net Receivables Growth Pattern

Below is the plot of the Net Receivables of Vaxcyte over the last few years. It is Vaxcyte's Net Receivables historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Vaxcyte's overall financial position and show how it may be relating to other accounts over time.
Net Receivables10 Years Trend
Slightly volatile
   Net Receivables   
       Timeline  

Vaxcyte Net Receivables Regression Statistics

Arithmetic Mean4,557,627
Geometric Mean685,474
Coefficient Of Variation196.00
Mean Deviation6,552,916
Median200,000
Standard Deviation8,933,104
Sample Variance79.8T
Range24.7M
R-Value0.71
Mean Square Error42.8T
R-Squared0.50
Significance0
Slope1,247,870
Total Sum of Squares1276.8T

Vaxcyte Net Receivables History

202624.9 M
202523.8 M
202420.7 M
20233.6 M
20221000 K
20211.2 M
2020300 K

About Vaxcyte Financial Statements

Vaxcyte investors use historical fundamental indicators, such as Vaxcyte's Net Receivables, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Vaxcyte. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Receivables23.8 M24.9 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Vaxcyte Stock Analysis

When running Vaxcyte's price analysis, check to measure Vaxcyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxcyte is operating at the current time. Most of Vaxcyte's value examination focuses on studying past and present price action to predict the probability of Vaxcyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxcyte's price. Additionally, you may evaluate how the addition of Vaxcyte to your portfolios can decrease your overall portfolio volatility.